You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

66 search results for: coexisting diseases

expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

53 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.

Itch: Neuroimmune Axis in Chronic Pruritic Skin <b>Diseases</b>

expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

11 min

Dermatology

A review of the neuroimmune axis and the mechanisms involved in perpetuating chronic itch in AD, PN, and CSU.

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

expert video

Evolving Topics in Type 2 Inflammation

49 min

Type 2 Inflammation

Drs. Eric Simpson, Jonathan Spergel, and Profs. Francesca Puggioni, Ian Pavord, Peter Hellings discuss emerging topics in type 2 inflammatory diseases

Podcast

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

15 min

Dermatology

Listen to the expert perspectives of Drs. Lisa Swanson and Weily Soong on clinical considerations in pediatric patients with atopic dermatitis.

expert video

Differences in Itch in AD, PN, and CSU

2 min

Dermatology

Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

9 min

Type 2 Inflammation

Prof. Stephan Weidinger discusses the impact of type 2 inflammation on disease burden and clinical outcomes in pediatric patients.

expert video

Shared and Unique Characteristics of AD, PN, and CSU

17 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

20 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region